Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma

被引:25
作者
Dai, Bojie [1 ]
Zhao, X. Frank [2 ]
Hagner, Patrick [1 ]
Shapiro, Paul [3 ]
Mazan-Mamczarz, Krystyna [1 ]
Zhao, Shuchun [5 ]
Natkunam, Yasodha [5 ]
Gartenhaus, Ronald B. [1 ,4 ]
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[4] Vet Adm Med Ctr, Baltimore, MD 21218 USA
[5] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
NON-HODGKINS-LYMPHOMAS; PROTEIN-KINASE; MALIGNANT-TRANSFORMATION; MYELOMA CELLS; DNA-DAMAGE; IN-VIVO; PATHWAY; INHIBITORS; MECHANISM; THERAPY;
D O I
10.1158/0008-5472.CAN-09-1606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MCT-1 oncogene was originally identified from lymphoma cell lines. Herein we establish that MCT-1 is highly expressed in 85% of human diffuse large B-cell lymphomas (DLBCL) and that knocking down MCT-1 by a specific short hairpin RNA in DLBCL cells induces apoptosis, supporting a critical role for MCT-1 in DLBCL cell survival. However, the mechanism underlying MCT-1 regulation is largely unknown. We find that MCT-1 is phosphorylated and up-regulated by extracellular signal-regulated kinase (ERK). Furthermore, by using a small inhibitory molecule targeting ERK we interrupted MCT-1 phosphorylation and stability. Significantly, cells with distinct levels of MCT-1 protein displayed differential sensitivity to ERK inhibitor-induced apoptosis. Treatment with the ERK inhibitor showed marked in vivo antitumor activity in a human DLBCL xenograft model. Our findings establish a functional molecular interaction between. MCT-1 and the MEK/ERK signaling pathway and suggest that the activation of MCT-1 function by its upstream kinase ERK plays an important role in lymphomagenesis. [Cancer Res 2009;69(19):7835-43]
引用
收藏
页码:7835 / 7843
页数:9
相关论文
共 30 条
[1]   Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach [J].
Abramson, JS ;
Shipp, MA .
BLOOD, 2005, 106 (04) :1164-1174
[2]  
[Anonymous], 2001, Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
[3]   New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].
Armitage, JO ;
Weisenburger, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795
[4]   Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse [J].
Dai, Bojie ;
Kim, Oekyung ;
Xie, Yingqiu ;
Guo, Zhiyong ;
Xu, Kexin ;
Wang, Bin ;
Kong, Xiangtian ;
Melamed, Jonathan ;
Chen, Hegang ;
Bieberich, Charles J. ;
Borowsky, Alexander D. ;
Kung, Hsing-Jien ;
Wei, Guo ;
Ostrowski, Michael C. ;
Brodie, Angela ;
Qiu, Yun .
CANCER RESEARCH, 2006, 66 (16) :8058-8064
[5]   Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism [J].
Dai, Y ;
Landowski, TH ;
Rosen, ST ;
Dent, P ;
Grant, S .
BLOOD, 2002, 100 (09) :3333-3343
[6]   Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells [J].
Dai, Yun ;
Chen, Shuang ;
Pei, Xin-Yan ;
Almenara, Jorge A. ;
Kramer, Lora B. ;
Venditti, Charis A. ;
Dent, Paul ;
Grant, Steven .
BLOOD, 2008, 112 (06) :2439-2449
[7]   MEK Wars, a new front in the battle against cancer [J].
Duesbery, NS ;
Webb, CP ;
Woude, GFV .
NATURE MEDICINE, 1999, 5 (07) :736-737
[8]   Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogenactivated protein kinase as a target for therapy [J].
Elenitoba-Johnson, KSJ ;
Jenson, SD ;
Abbott, RT ;
Palais, RA ;
Bohling, SD ;
Lin, ZS ;
Tripp, S ;
Shami, PJ ;
Wang, LY ;
Coupland, RW ;
Buckstein, R ;
Perez-Ordonez, B ;
Perkins, SL ;
Dube, ID ;
Lim, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (12) :7259-7264
[9]   Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy [J].
Friday, Bret B. ;
Adjei, Alex A. .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :342-346
[10]   Regulation of androgen receptor activity by tyrosine phosphorylation [J].
Guo, Zhiyong ;
Dai, Bojie ;
Jiang, Tianyun ;
Xu, Kexin ;
Xie, Yingqiu ;
Kim, Oekyung ;
Nesheiwat, Issa ;
Kong, Xiangtian ;
Melamed, Jonathan ;
Handratta, Venkatesh D. ;
Njar, Vincent C. O. ;
Brodie, Angela M. H. ;
Yu, Li-Rong ;
Veenstra, Timothy D. ;
Chen, Hegang ;
Qiu, Yun .
CANCER CELL, 2006, 10 (04) :309-319